6. Ignores failure of competitors
VERY good point - Belviqs competitor Qysmia has REMs, is debt laden and is being operated by a hedge fund.
Contrave by OREX may not be approved, has a risky profile and is also buried in debt.
As an analyst he fails. Hes unable to see the whole picture. What concerns me is he has become the only remnant of the $150.M B sales. 22,000 doctors will be 60 by summer. 7500 will be 20k on the Rx side
Not sure about that. SA is known for anonymous unqualified writers, so you get what you pay for. Id like to try the lawsuit route
After this idiot lists all of Arena's projected expenses, given out a day ago by people who know, the clown paints a bleak picture of approx $129m in costs for 2014. Only on the very last line does he state (as we al know) that Arena has $230M in cash on hand.
Tell me Spencer how many biotechs do you know that can spend $129M over the next year and still have $100M left over PLUS whatever revenue they do generate?
Get lost you CLOWN
Michelle Obama was pumping obesity and Nutri-system was trying to figure out why their sales were dropping. Let me know if you can figure out any connections students and don't forget Weight Watchers
I don't predict earnings,,, but this price is not in line to where Arena is financially
. This could be current shorts last breath if ARNA impresses today,
Im NOT saying it will hit the moon.. Im saying it will rise steadily until news or Rx counts DO place shares into orbit for good..